ExSight Ventures invests in RevOpsis Therapeutics to further AMD treatment candidate

Image credit: AdobeStock/jirsak

ExSight Ventures invested in RevOpsis Therapeutics, a company developing a novel class of multispecific antibody-based treatments designed to address significant unmet needs in ophthalmology. The company states that initial focus will be on the developing treatment for patients with wet age-related macular degeneration (AMD) and diabetic eye disease.

Firas Rahhal, MD, General Partner at ExSight Ventures and Retina Vitreous Associates Medical Group in Los Angeles stated in the news release, "We are thrilled to support RevOpsis in its mission to bring breakthrough therapies to patients suffering from vision-threatening conditions. Our investment reflects our strong belief in both the scientific foundation of RevOpsis' platform and the experienced leadership team driving its development."

Similarly, Ram Bhandari, MD, Chief Executive Officer and Co-founder of RevOpsis Therapeutics, spoke to this partnership and its potential to further research and treatments. He said, "ExSight Ventures is a leading investor in the ophthalmology space, and their support is a strong validation of our approach. This partnership will help us advance our pipeline toward clinical development and bring us closer to providing patients with more effective and longer-lasting treatment options. ExSight Ventures has a proven track record of backing companies developing innovative solutions in eye care, and this investment further demonstrates its commitment to supporting the next wave of therapeutic breakthroughs in ophthalmology."

What is RevOpsis Therapeutics?

RevOpsis Therapeutics is a privately held biopharmaceutical company working on innovation in ophthalmic therapies. Guided by a team of leading physicians, scientists, and business leaders, the company is working to develop and commercialize treatments for chronic multifactorial diseases.

To reach their goals, the company employs its proprietary Rev-Mod platform. RO-104 is RevOpsis' current lead candidate, which is an engineered as a first-in-class fully human modular tri-specific biologic designed to address all 3 clinically validated dominant angiogenic pathways (VEGF-A, VEGF-C, Ang-2) implicated in retinal vascular disease progression, including neovascular age-related macular degeneration (nAMD).

What is ExSight Ventures?

ExSight Ventures (EV) is a venture capital firm built to serve early-stage life sciences. With deep clinical expertise and venture discipline, the company is committed to backing pioneering teams advancing breakthrough innovations to patients who need them most.

Reference:

1.ExSight Ventures Invests in RevOpsis Therapeutics to Advance Innovative Treatments for Blinding Eye Diseases. ExSight Ventures. News Release. September 16, 2025. Accessed September 17, 2025. https://www.prnewswire.com/news-releases/exsight-ventures-invests-in-revopsis-therapeutics-to-advance-innovative-treatments-for-blinding-eye-diseases-302557479.html